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Introduction: Thyroid hormones (THs) are especially important for brainmaturation and development during the
fetal period and childhood. Several epidemiological studies have assessed the possible association between expo-
sure to perﬂuoroalkyl substances (PFAS) and thyroid outcomes during the early stages of life. We aimed to re-
view this evidence.
Methods:We conducted a systematic review in compliance with the PRISMA Statement (search conducted in
PubMed and Embase, as well as in the citations of the selected articles). We chose studies if they dealt with
thyroid-stimulating hormone (TSH), triiodothyronine (T3), thyroxin (T4), or thyroid dysfunctions, and
perﬂuorohexane sulfonate (PFHxS), perﬂuorooctanoic acid (PFOA), perﬂuorooctane sulfonate (PFOS) or
perﬂuorononanoic acid (PFNA) measured in the blood of pregnant women and/or children up to 19 years old.
Results:We included in this review three cross-sectional, one case-control, and six cohort studies (publication:
2011–2015), focusing on prenatal life (n = 7), childhood (n = 2) or both periods (n = 1). We observed a
high degree of heterogeneity across studies in terms of sampling time (different gestational weeks, at birth, or
childhood), outcomes, adjustment for potential confounders, and statistical approach. We found some evidence
of a positive association between PFHxS and PFOS exposure and TSH levels measured in maternal blood, and
PFNA and TSH levels measured in the blood of boys aged ≥11 years.
Conclusion: Although there is a small number of studies with comparable data, we found some consistency of a
positive association betweenmaternal or teenage male exposure to some PFAS and TSH levels based on the cur-
rent literature. However, further studies are required to conﬁrm these possible relationships.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Perﬂuoroalkyl substances (PFAS) are synthetic chemicals with
unique properties, such as insolubility in both organic solvents and
water, and the ability to repel oils and water. They have been
manufactured for industrial applications since the 1940s, and they
are found and used in many common industrial and consumer prod-
ucts such as ﬁre-ﬁghting foams, alkaline cleaners, ﬂoor polishes,
photographic ﬁlms, shampoos, ant insecticides, soil- and stain-
resistant coatings for fabrics, carpets and leather, as well as in
grease- and oil-resistant coatings for paper products, among others
(OCDE, 2005; Renner, 2001; WHO, 2013). In the general population,
the main routes of exposure to these substances are via food, food
packaging and drinking water (Domingo et al., 2012; Vestergren
et al., 2008). Nearly all individuals, including pregnant women and
children, in the many populations studied worldwide (Fromme et al.,
2009; Kato et al., 2011; Manzano-Salgado et al., 2016; Mondal et al.,
2012; Mørck et al., 2015; Zhao et al., 2012), showed measurable blood
concentrations of four PFAS (perﬂuorohexane sulfonate [PFHxS],
perﬂuorooctanoic [PFOA], perﬂuorooctane sulfonate [PFOS], and
perﬂuorononanoic acid [PFNA]). Although there have been phase-out
agreements regarding the production of certain PFAS by the industry
in U.S. and Europe (WHO, 2013), due to their ubiquitous presence,
long half-life in humans (Bartell et al., 2010; Olsen et al., 2007), and a
tendency for bioaccumulation and biomagniﬁcation (WHO, 2013), ex-
posure to this class of compounds will persist for many years, thereby
making them a potential threat to humans.
Concern about exposure to PFAS has increased after the publication
of recent studies showing that these chemicals have endocrine-
disrupting properties and, among their possible health effects, PFAS
may have the ability to impair thyroid function (Jensen and Leffers,
2008). Our review focuses on PFAS and thyroid disruption during
the prenatal and childhood periods because thyroid hormones
(THs) are especially important during brain maturation and the de-
velopment of the fetus and children (Dussault and Ruel, 1987). THs
are involved in the processes of dendritric and axonal growth, synap-
togenesis, neurogenesis, and myelination during intrauterine life
(Bernal, 2007). After birth, they are still essential, since some of
these neurodevelopmental processes, such as myelination, are not
completed until adolescence (Rice and Barone, 2000; Schug et al.,
2015) and they also play a role in the behavior and cognitive func-
tions of the young and adolescent brain (Anderson, 2001). In fact,
disorders involving TH availability, even subclinical maternal hypo-
thyroidism (Haddow et al., 1999) or subtle changes in TH homeosta-
sis during the ﬁrst years of life (Freire et al., 2010; Julvez et al., 2013)
may lead to delays in child neuropsychological development. Addi-
tionally, TH deﬁciency during infancy, childhood and puberty causes
growth delay and precocious puberty in both sexes, and hirsutism in
females (Papi et al., 2007). Finally, postnatal alterations of TH levels
are also correlated with a variety of adverse effects in the pulmonary
(Krude et al., 2002; Mendelson and Boggaram, 1991) and cardiovas-
cular (Asvold et al., 2007; Biondi et al., 2005; Osman et al., 2002) sys-
tems. Therefore, the possible effects of PFAS on thyroid function
during fetal and child life is a matter of public concern.
Prompted by the worldwide exposure to four PFAS (PFHxS, PFOA,
PFOS, and PFNA) and the essential role of the thyroid system in the de-
velopment and normal functioning of the body, we aimed to assess the
evidence of associations betweenexposure to PFAS and thyroid function
in pregnant women and children up to 19 years old.
2. Methods
We developed a protocol and performed a systematic review in ac-
cordance with the general principles recommended in the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
statement (Moher et al., 2010).
2.1. Eligibility criteria and search strategy
Studies selected for the reviewwere those carried out in populations
of pregnant women or children up to 19 years old, written in English or
Spanish, and published before the endof December 2015. In thisﬁrst se-
lection of articles, we did not impose any restrictions on outcomes if at
least oneof the four chemicals (PFHxS, PFOA, PFOS, PFNA) or the generic
PFC, PFAA, and PFAS were included (more details about search syntax
can be found in Supplementary data). We did not include other PFAS
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in our review since the current published literature on their possible as-
sociation with thyroid function is still too scarce. We also located some
relevant studies after reading citations from the selected articles.
2.2. Study selection criteria
We used the PICOS framework (Liberati et al., 2009) to establish the
criteria for selecting the studies to be included in this review, since it of-
fers a structured approach for framing questions usingﬁve components,
as follows. Participants: Pregnant women and children up to 19 years
old. Studies on general or occupational populations were also eligible
if results were stratiﬁed by sex (specifying the pregnant status of
women) or age of the children, and only those results were included
in this review. Exposures: Studies on directmeasurement of PFAS in a bi-
ological matrix or indirect exposure estimations. Comparators: Continu-
ous PFAS levels or groups categorized according to individual PFAS
levels. Outcomes: TH levels (thyroid-stimulating hormone [TSH], total
triiodothyronine [TT3], free T3 [FT3], thyroxin [T4], and free T4 [FT4])
or thyroid dysfunctions. Study design: Cross-sectional, case-control,
and cohort studies.
Two reviewers screened the titles and abstracts independently. Res-
olution in case of disagreement was achieved by discussion and consul-
tation with a third reviewer. Data were abstracted by one reviewer and
checked by the other two, and all of themalso assessed themethodolog-
ical quality of the articles that were ﬁnally included.
2.3. Assessment of the methodological quality of the articles
A validated tool to evaluate the methodological quality of observa-
tional studies is still lacking. As in some previous systematic reviews
(Olmos et al., 2008; Ricci-Cabello et al., 2010; González-Alzaga et al.,
2014; Rodríguez-Barranco et al., 2013), we assessed themethodological
quality of the studies using the nine items included in theMethods sec-
tion of the STROBE statement checklist (Strengthening the Reporting of
Observational Studies in Epidemiology Statement) (von Elm et al.,
2014). Studies with low scores according to the STROBE checklist
were excluded from the review. For more information about the
STROBE checklist items used, see Supplementary data, Table S1.
2.4. Data extraction and synthesis
Tables 1–5 and Fig. 1 summarize the data extracted from the select-
ed articles, which include information on design, location, sample size,
date, outcomes, PFAS, matrices, time of sample collection, statistical
analyses, covariates included in the models, and main ﬁndings (esti-
mates of the fully adjusted models are presented in tables). For all the
studies reviewed, the summarized information was based on results
presented in the original papers except for Tables 2 and 4 and Fig. 1,
since some data (sample size, percentiles, minimums and/or maxi-
mums) not included in the articles were provided by authors (see foot-
notes for further information). Publicly available data from the 2011–
2012 National Health and Nutrition Examination Survey (NHANES), a
nationally representative sample of non-institutionalized U.S. residents
(NHANES, 2015),was used to replicate the same database thatwas used
in Lewis et al. (2015). In that study the authors reported sex-stratiﬁed
PFAS concentrations in boys (n = 158) and girls (n = 145) aged 12–
19 years, while we present these values for all children (n = 303) in
Table 2 and Fig. 1.
3. Results
The database search identiﬁed 380 citations, and we identiﬁed
another 16 citations from additional searches in other sources. A
total of 319 citations were excluded at the title/abstract stage (unre-
lated to study topic or duplicates), leaving 77 articles for examina-
tion of the full text. Of these, 66 were later excluded because they
did not meet the inclusion criteria. Hence, altogether, we identiﬁed
eleven eligible studies from the searches (PRISMA ﬂow diagram,
see Supplementary data, Figure S1). One of them (Inoue et al.,
2004) was a very preliminary and rather descriptive study on the as-
sociation between PFAS and THs and achieved a low quality score ac-
cording to the STROBE checklist. Therefore, this article was not
included in the review. All included studies (n = 10) achieved a
high score according to the STROBE checklist (Table 1).
Various design features (i.e., choice of population, outcomes, co-
variates, and analysis type) could all be important in generating dif-
ferences in results between studies, and these attributes are
summarized in the sections that follow. The articles have been
grouped by study populations and PFAS examined, and within each
group the differences in design features generally seem to be limited,
the most noticeable discrepancies being found in the mean expo-
sures by study for some PFAS and the inclusion of some of the
confounders.
3.1. Study population
A description of the epidemiologic studies is shown in Table 1. The
studies were conducted in Asia, Europe, and North America. Sample
size varied fromaround40 to N10,000 participants and theparticipation
rate, when provided (Lin et al., 2013; Lopez-Espinosa et al., 2012b;
Wang et al., 2013; Webster et al., 2011), ranged between 7.6 and 95%
(data not shown). The design of the studies was either cross-sectional
(n = 3), case-control (n = 1), or cohort (n = 6), although some of
the latter also performed cross-sectional analyses. Chan et al. (2011)
conducted a case-control study among women with or without
hypothyroxinemia, Lin et al. (2013) focused on adolescents and young
adults with abnormal urinalysis during childhood, and Lopez-Espinosa
et al. (2012b) conducted a study in pregnant mothers and children
from a community living near a ﬂuoropolymer manufacturing facility.
The remaining studies focused on pregnant women and children from
general populations. Most authors adjusted the statistical analyses for
maternal or child age (n=9). The other variables of adjustment present
a greater variation among studies (Table 1).
3.2. PFAS
3.2.1. Blood compartments
Seven out of the ten studies used serum for contaminant analysis,
and the rest used plasma (Tables 1 and 2).
3.2.2. Time of sampling and analysis
During pregnancy, a total of six studies determined PFAS concentra-
tions in the second (n=4) or third (n=2) trimester, and one of these
studies also measured these chemicals in cord serum. In addition, one
study measured PFAS only in cord plasma, another used modeled ma-
ternal serum concentrations during the ﬁrst trimester of pregnancy in
addition to serummeasures in children aged 1–17 years, and two stud-
ies measured these contaminants in the plasma or serum of children
aged 12–19 years (Tables 1 and 2). In all the studies, PFAS were mea-
sured using liquid chromatography separation coupledwithmass spec-
trometry (LC/MS). The ranges of the limits of detection (LODs) or
quantiﬁcation (LOQs) were 0.05–0.5, 0.03–1.5, 0.04–0.5 and 0.04–
0.75 ng/mL, for PFHxS, PFOA, PFOS, and PFNA, respectively (data not
shown).
3.2.3. PFAS concentrations
PFOA and PFOSwere measured in all the studies, while PFHxS and
PFNA were determined in seven of them. PFOA levels were higher in
the population living in the vicinity of a Teﬂonmanufacturing facility
(child serum median: 29.3 ng/mL, modeled in utero serum:
11.5 ng/mL) (Lopez-Espinosa et al., 2012b) compared to the rest of
the populations (median range: 0.89–4.3 ng/mL). PFOS was the
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most commonly detected (N80–100%), with a greater variation in its
concentrations (median range: 1.3–20 ng/mL). Less variation was
observed for PFHxS (median range: 0.3–1.1 ng/mL) and PFNA (0.4–
1.5 ng/mL) among studies, and concentrations were lower compared
to the other PFAS (Table 2 and Fig. 1).
3.3. TH outcomes
3.3.1. Blood compartments
Eight, one and one studies used serum, plasma and blood for hor-
mone analysis, respectively (Tables 1 and S2).
Table 1
Description of epidemiological studies on prenatal and child PFAS exposure and thyroid function.
Study Design Location
(Date)
Population (n),
age
PFAS PFAS
matrix
TH TH matrix Statistical analysis Adjusted variables MQ
Lewis et al.
(2015)
C-S U.S.
(2011-12)
NHANES
children (303),
range: 12-19 yrs
PFHxS
PFOA
PFOS
PFNA
Child
serum
TSH Child serum Multiple linear regression models
between log2(PFAS) and log2(THs).
Sensitivity analysis with categorized
PFAS into quartiles
Child age, BMI, poverty
income ratio, race/ ethnicity,
and serum cotinine
H
TT4
FT4
TT3
FT3
Berg et al.,
2015
C(P) Norway
(2007-09)
Pregnant
women (391),
median (range):
32 (18-43) yrs
PFHxS
PFOA
PFOS
PFNA
Maternal
serum
(2nd T)
TSH Maternal
serum (2nd
T, 3 days,
and 6 wks
after birth)
Mixed effects models between PFAS
(in quartiles) and mean effect of three
repeated measurements of THs
(log-transformed)
Parity, maternal age, BMI,
and thyroxin binding
capacity
H
TT4
FT4
TT3
FT3
de Cock et al.,
2014
C(P) Zwolle,
Netherlands
(2011-13)
Pregnant
women (83),
mean (range):
32.6 (23-40) yrs;
neonates (83)
PFOA
PFOS
Cord
plasma
TT4 Infant
blood (4-7
days of age)
Multiple linear regression models
between PFAS (in quartiles) and TT4
stratiﬁed by sex (by means of an
interaction term included in models)
Maternal age, GWG, BMI,
smoking, alcohol intake,
thyroid problem, thyroid
medication, parity,
gestational age, and birth
weight
H
Wang et al.,
2014
C(P) Taiwan
(2000-01)
Pregnant
women (285),
mean: 28.8 yrs;
neonates (116)
PFHxS
PFOA
PFOS
PFNA
Maternal
serum
(3rd T)
TSH Maternal
serum (3rd
T)
Cord serum
Multiple linear regression models
between PFAS and THs
Maternal age, education,
previous children, neonatal
sex, and type of delivery
H
TT4
FT4
TT3
Webster et al.,
2014
C(P) Vancouver,
Canada
(2007-08)
Pregnant
women (152),
mean (range):
34 (25-43) yrs
PFHxS
PFOA
PFOS
PFNA
Maternal
serum
(2nd T)
TSH Maternal
serum
(twice in
2nd T)
Mixed effects linear regression
models between PFAS and THs with a
random intercept for subject.
Interaction between TPOAb status and
PFAS also included in models
Gestational age at blow
draw, time of day of
sampling, and TPOAb status
H
TT4
FT4
Lin et al., 2013 C-S Taipei,
Taiwan
(2006-08)
Children (212),
range: 12-19 yrs
PFOA
PFOS
PFNA
Child
plasma
TSH Child serum Multiple linear regression models
between categorizeda PFAS and
ln(TSH) or FT4 stratiﬁed by sex
Child age, sex, smoking and
drinking status
H
FT4
Wang et al.,
2013
C-S Norway
(2003-04)
Pregnant
women (903),
mean (range):
30 (18-44) yrs
PFHxS
PFOA
PFOS
PFNA
Maternal
plasma
(17-18
gws)
TSH Maternal
plasma
(17-18
gws)
Multiple linear regression models
between PFAS (continuous or
quartiles) and ln(TSH)
Logistic regression with
dichotomizedb TSH as the outcome
Maternal age, HDL levels,
total seafood intake, parity,
inter-pregnancy interval, and
gestational age at blood draw
H
Lopez-Espinosa
et al., 2012b
C(R) Mid-Ohio
Valley, U.S.
(1987-06)
Pregnant
women (4,713),
mean: 26 yrs;
children
(10,725), range:
1-17 yrs
PFOA
PFOS
PFNA
Modeled
serum
levels in
utero
(1st T)
Child
serum
TSH Child serum
(1-17 yrs)
Multiple linear regression models
between ln(PFAS) or PFAS in quartiles
and ln(TSH) or TT4. Same analyses
stratiﬁed by sex and age groups.
Logistic regression models with
reported thyroid diseasec and
subclinicald hypo/hyperthyroidism as
the outcomes
Child age, sex, and month of
sampling
H
TT4
Chan et al.,
2011
C-C Alberta,
Canada
(2005-06)
Pregnant
women (271),
mean (range):
31 (20-45) yrs
PFHxS
PFOA
PFOS
Maternal
serum
(15-16
gws)
TSH Maternal
serum
(15-16
gws)
Adjusted conditional logistic
regression models between ln(PFAS)
in maternal serum and
hypothyroxinemiae
Maternal age, weight, race,
and gestational age at blood
draw
H
FT4
Kim et al., 2011 C(P) Seoul,
Gumi,
Cheongju
South Korea
(2008-09)
Pregnant
women (44),
mean (range):
32 (22-44) yrs;
newborns (43)
PFHxS
PFOS
PFOAf
Maternal
serum
(3rd T)
Cord
serum
TSH Cord serum Pearson correlations between
ln(PFAS) and ln(THs) with- and
without adjustment for inﬂuential
covariates
Maternal age, BMI, and
gestational age at blood draw
H
TT4
TT3
BMI: body mass index; C-C: case-control; C(P): cohort (prospective); C(R): cohort (retrospective); C-S: cross-sectional; FT3: free triiodothyronine; FT4: free thyroxin; GWG: gestational
weight gain; gws: gestational weeks; H: high; HDL: high density lipoprotein; ln: natural log transformed; MQ: methodological quality; n: sample size; PFAS: perﬂuoroalkyl substances;
PFHxS: perﬂuorohexane sulfonate; PFNA: perﬂuorononanoic acid; PFOA: perﬂuorooctanoic acid; PFOS: perﬂuorooctane sulfonate; T: trimester; TH: thyroidhormone; TPOAb: thyroid per-
oxidase antibody (dichotomized according to clinical guidelines, high: ≥9 IU/mL versus normal: b9 IU/mL); TSH: thyroid-stimulating hormone; TT4: total thyroxin; TT3: total triiodothy-
ronine; wks: weeks; yrs: years.
Some authors included adults in their articles (Lewis et al. and Lin et al.), this information has not been discussed in this review.
a Cut-off values: 50th, 75th and 90th percentiles for PFOA; 25th, 50th and 75th percentiles for PFOS, and 60th and 90th percentiles for PFNA.
b TSH above the 95th percentile (7.5 μIU/mL).
c For three categories of self-reported disease: any thyroid disease, hypothyroidism, and thyroid disease plus thyroid medication.
d TT4 within the normal reference range (4.5–12 μg/dL) and TSH N5.97, N4.84, N4.5 μIU/mL in children b6, 6–10, 11-17 years old for subclinical hypothyroidism and TSH b0.7, b0.6,
b0.45 μIU/mL in children b6, 6–10, 11-17 years old for subclinical hyperthyroidism. Children who self-reported thyroid disease and/or thyroid medication were excluded.
e Hypothyroxinemia: deﬁned by authors as normalmaternal TSH levelswith no evidence of hyperthyroidism (0.15-≤4mU/L) andmaternal FT4 levels in the lowest 10th percentile (≤8.8
pmol/L) of the sample. Controls: normal TSH (0.15-≤4 mU/L), and FT4 between the 50th and 90th percentiles (12–14.1 pmol/L).
f Kim also measured PFNA but associations with THs were not studied and, therefore, it has not been included in this review. In this article, all samples were collected during the 3rd
trimester of pregnancy except seven of them collected at 20-25 weeks of gestation.
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3.3.2. Time of sampling and analysis
During pregnancy, THs were measured in the second (n = 4) or
third (n = 1) trimester, as well as in cord serum (n = 2). Berg et al.
(2015) collected two additional blood samples at 3 days and 6 weeks
after delivery andWebster et al. (2014)measured hormones twice dur-
ing the second trimester of pregnancy. Also after birth, THs were mea-
sured in newborn blood (n= 1) or child serum (n = 3) (Table 1). All
studies used different types of immunoassays to determine TH levels
(data not shown).
Four of the studies on TH levels excluded participants who reported
any thyroid disease and/or were taking thyroid medication
(Lopez-Espinosa et al., 2012b; Wang et al., 2013, 2014; Webster et al.,
2014), one of them (Webster et al., 2014) also excluded women with
other endocrine alterations, such as diabetes mellitus, which is known
to affect TH levels (data not shown), and another article (de Cock
et al., 2014) adjusted models for data on thyroid gland problems and
thyroid medication use (Table 1).
3.3.3. TH levels
TSHwas assessed in nine studies, TT4 in seven, FT4 in six, TT3 in four,
and FT3 in two (Tables 1 and S2). Median ranges of TSH and TT4 levels
were 0.65–6.65 mIU/L and 107.7–145 nmol/L, respectively, in both the
prenatal and at–birth studies. Respective data during childhood were
1.4–1.83 mIU/L and 95.2–99.1 nmol/L, and de Cock et al. (2014) found
mean levels of TT4 of 85.6 and 89.6 mIU/L in infant boys and girls,
respectively. Few studies measured other hormones (FT4, TT3 and
FT3) during these two periods to compare results. In the only study
measuring maternal levels during pregnancy and after birth (Berg
et al., 2015), levels of TSH, TT4, and TT3 decreased after birth, while
levels of the free hormones (FT4 and FT3) increased (Table S2).
3.3.4. Thyroid dysfunction outcomes
The outcome investigated by Chan et al. (2011) was
hypothyroxinemia in pregnant women. Lin et al. (2013) andWang et al.
(2013) investigated dichotomized TSH levels as the outcome, but the for-
mer did not stratify by age and the results are not included in this review.
Webster et al. (2014) assessed the effect of PFAS inwomenwith high thy-
roid peroxidase antibody (TPOAb) levels, which is a marker of autoim-
mune hypothyroidism, including the interaction between TPOAb status
and PFAS in the models. Berg et al. (2015) studied the association with
subclinical hypothyroidism based on TH levels. Lopez-Espinosa et al.
(2012b) investigated the association with self-reported thyroid disease,
thyroid medication plus thyroid disease, hypothyroidism, and subclinical
hypo/hyperthyroidism based on TH levels (Table 1).
3.4. Analysis of the relation between PFAS and THs
Seven studies examined the association between prenatal PFAS ex-
posure and TH levels measured during the prenatal, neonatal or child
periods (Table 3) and three cross-sectional studies between child PFAS
and TH levels (Table 4).
Table 2
Summary of PFAS concentrations (ng/mL).
Study Detected levelsa.
Statistics
Matrix PFHxS PFOA PFOS PFNA
Maternal PFAS
Berg et al., 2015 % NLOD Maternal serum 99 100 N80 100
Median (P25, P75) 0.44 (0.28, 0.66) 1.53 (0.99, 2.16) 8.03 (5.76, 11.01) 0.56 (0.43, 0.78)
Webster et al., 2014 % NLOD Maternal serum 84 99 100 62
Median (P25, P75) 1.0 (0.7, 1.7) 1.7 (1.0, 2.4) 4.8 (3.2, 6.5) 0.6 (b0.5, 0.8)
Wang et al., 2014 % NLOQ Maternal serum 78 87 100 96
Median (P25, P75) 0.81 (0.30, 1.35) 2.39 (1.54, 3.40) 12.73 (9.65, 17.48) 1.51 (0.85, 2.51)
Wang et al., 2013 % NLOQ Maternal plasma 99 100 100 99
Median (P25, P75) 0.60 (0.43, 0.84) 2.15 (1.57, 2.95) 12.81 (10.13, 16.49) 0.39 (0.28, 0.51)
Lopez-Espinosa et al.,
2012b
% NLOD Maternal serum (modeled
in utero)
- 100 - -
Median (P25, P75) - 11.5 (5.36, 37.2) - -
Chan et al., 2011 % NLOD Maternal serum in cases 94 89 99 -
Median (P25, P75) 0.99 (0.58, 2.28) 1.63 (0.74, 2.61) 7.75 (5.19, 11.44) -
Maternal serum in controls 93 93 100 -
0.94 (0.54, 1.96) 1.50 (0.89, 2.55) 8.22 (5.19, 11.91) -
Kim et al., 2011 % NLOD Maternal serum 100 100 100 -
Median (P25, P75) 0.55 (0.46, 0.85) 1.46 (1.15, 1.91) 2.93 (2.08, 4.36) -
Cord PFAS
de Cock et al., 2014 % NLOQ Cord plasma - 100 100 -
Median (P25, P75)b - 0.89 (0.59, 1.18) 1.6 (1.0, 2.08) -
Kim et al., 2011 % NLOD Cord serum 100 100 100 -
Median (P25, P75) 0.34 (0.27, 0.51) 1.15 (0.95, 1.86) 1.26 (0.81, 1.82) -
Child PFAS
Lewis et al., 2015 % NLOD Child serum 99 100 100 100
Median (P25, P75) 1.05 (0.66, 1.92) 1.71 (1.32, 2.35) 4.19 (2.71, 6.22) 0.75 (0.53, 1.16)
Lin et al., 2013 % NLOD Child plasmac - 61 98 42
Median (P25, P75) - 4.29 (0.75, 6.78) 8.0 (4.97, 11.43) 0.38 (0.38, 3.13)
Lopez-Espinosa et al.,
2012b
% NLOD Child serum - 100 99.8 99
Median (P25, P75) - 29.3 (13.1, 67.7) 20.0 (14.5, 27.8) 1.50 (1.20, 2.00)
- Not studied; LOD: limit of detection; LOQ: limit of quantiﬁcation; P: percentile; PFAS: perﬂuoralkyl substances; PFHxS: perﬂuorohexane sulfonate; PFNA: perﬂuorononanoic acid; PFOA:
perﬂuorooctanoic acid; PFOS: perﬂuorooctane sulfonate.
Somedata not included in the articleswas provided by authors (percentiles: Berg et al. and deCock et al.; %NLOD,median andpercentiles for children aged 12-19 years: Lin et al.). Database
used in Lewis et al. has been replicated using publicly-available data from NHANES, 2011–2012 (NHANES, 2015), since Lewis et al. reported sex-stratiﬁed PFAS concentrations and we
present data for both girls and boys.
a Imputation of non-detected concentrations: based on expected values assuming a log-normal distribution in Wang et al. (2014); LOD/√2 in Berg et al., Webster et al., Kim et al., and
Lewis et al.; LOQ/√2 in de Cock et al. and Wang et al. (2013); and LOD/2 in Lin et al., Lopez-Espinosa et al., and Chan et al.
b n = 64.
c Matrix taken from the "Material and Methods" section of the article.
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Table 3
Summary of associations between prenatal PFAS exposure (ng/mL) and THs measured at different lifestages.
Study Expression of results TH matrix (units) n Associations between PFAS and THs
PFHxS PFOA PFOS PFNA
Maternal PFAS
Berg et al., 2015 Estimated mean differences in
THsa (95% CI) across PFAS Qs
Maternal TSH (mLU/L) 375 NS NS ↑: Q2: 0.18 (0.06, 0.31)a NS
↑*: Q3: 0.26 (0.13, 0.40)
↑*: Q4: 0.35 (0.21, 0.50)
Webster et al. (2014) β (95% CI) per IQRb ng/mL
increase in PFAS
Maternal TSH (mIU/L) 151 ↑: 0.01 (-0.05, 0.07) ↑: 0.1 (-0.05, 0.3) ↑: 0.1 (-0.03, 0.2) ↑*: 0.2 (0.01, 0.3)
Maternal TT4 (nmol/L) 151 ↓: -0.8 (-2, 0.6) ↓: -2 (-6, 2) ↓: -2 (-5, 1) ↓: -2 (-5, 2)
Maternal FT4 (pmol/L) 150 ↓: -0.02 (-0.1, 0.07) ↓: -0.06 (-0.3, 0.2) ↑: 0.03 (-0.2, 0.2) ↓: -0.03 (-0.2, 0.2)
Wang et al., 2014 β (95% CI) per 1 ng/mL increase
in PFAS
Maternal TSH (μIU/mL) 283 ↑*: 0.105 (0.002, 0.207) ↑: 0.011 (-0.057, 0.078) ↓: -0.005 (-0.024, 0.013) ↑: 0.033 (-0.046, 0.112)
Maternal TT4 (μg/dL) 274 ↓: -0.130 (-0.316, 0.057) ↑: 0.011 (-0.108, 0.130) ↑: 0.019 (-0.016, 0.053) ↓*: -0.189 (-0.333, -0.046)
Maternal FT4 (ng/dL) 285 ↓: -0.010 (-0.023, 0.003) ↓: -0.003 (-0.012, 0.005) ↑: 0.001 (-0.002, 0.003) ↓*: -0.019 (-0.028, -0.009)
Maternal TT3 (μg/dL) 276 ↓: -0.002 (-0.005, 0.001) ↓: -0.000 (-0.002, 0.009) ↑: 0.000 (-0.002, 0.001) ↓: -0.001 (-0.003, 0.002)
Cord TSH (μIU/mL) 114 ↑: 0.493 (-1.449, 2.434) ↓: -0.498 (-1.464, 0.468) ↓: -0.083 (-0.292, 0.127) ↓: -0.361 (-0.955, 0.234)
Cord TT4 (μg/dL) 116 ↑: 0.002 (-0.495, 0.500) ↑: 0.128 (-0.094, 0.350) ↑: 0.032 (-0.024, 0.087) ↓*: -0.213 (-0.384, -0.042)
Cord FT4 (ng/dL) 92 ↓: -0.030 (-0.098, 0.039) ↓: -0.029 (-0.062, 0.004) ↑: 0.001 (-0.006, 0.008) ↑: 0.001 (-0.021, 0.023)
Cord TT3 (μg/dL) 112 ↓: -0.001 (-0.007, 0.004) ↓: -0.001 (-0.004, 0.001) ↑: 0.000 (-0.000, 0.001) ↓*: -0.002 (-0.004, -0.001)
Wang et al., 2013 β (95% CI) per 1 ng/mL increase
in PFAS
Maternal lnTSH (μIU/mL) 903 ↑: 0.013 (-0.043, 0.070) ↓: -0.0001 ( -0.045, 0.44) ↑*: 0.008 (0.001, 0.016) ↑: 0.165 (-0.023, 0.353)
Lopez-Espinosa et al., 2012b % change (95% CI) in TH per IQRb
ng/mL increase in modeled in
utero PFOA
Child TSH (μIU/mL) 476 (1-5 yrs) - ↓: -3.4 (-8.8, 2.4) - -
1,405 (6-10 yrs) - ↓: -1.5 (-4.9, 2.1) - -
2,741 (11-17 yrs) - ↑: 0.1 (-2.2, 2.5) - -
4,622 (1-17 yrs) - ↓: -0.5 (-2.4, 1.5) - -
Child TT4 (μg/dL) 484 (1-5 yrs) - ↑*: 2.0 (0.1, 3.9) - -
1,410 (6-10 yrs) - ↑: 0.9 (-0.3, 2.1) - -
2,744 (11-17 yrs) - ↓: -0.7 (-1.5, 0.2) - -
4,638 (1-17 yrs) - ↓: -0.1 (-0.8, 0.6) - -
Kim et al., 2011 Pearson correlation coefﬁcient
(r)
Cord TSH (μIU/mL) 29 ↑: 0.091 ↑*: 0.443 ↑: 0.109 -
Cord TT4 (μg/dL) 33 ↑: 0.030 ↓: -0.071 ↓: -0.181 -
Cord TT3 (ng/dL) 32 ↓: -0.261 ↓: -0.238 ↓*: -0.414 -
Cord PFAS
de Cock et al., 2014 β (95% CI) of each PFAS Q
compared to Q1, by sex
Newborn TT4 (nmol/L) 52 - ↑:Q2b: 7.9 (-18.04, 33.92) ↓:Q2b: -7.9 (-31.56, 15.74) -
52 ↓:Q3b: -2.1 (-20.94, 16.78) ↓:Q3b: -16.5 (-40.32, 7.34)
52 ↑:Q4b: 6.2 (-16.08, 28.50) ↓:Q4b: -9.6 (-32.57, 13.31)
52 ↓:Q2g: -5.9 (-26.75, 14.94) ↓:Q2g: -1.3 (-30.45, 27.94)
52 ↑:Q3g: 11.8 (-19.08, 42.72) ↑:Q3g: 4.5 (-25.95, 34.92)
52 ↑*:Q4g: 38.6 (13.34, 63.83 ↑:Q4g: 15.9 (-10.67, 42.40)
Kim et al., 2011 Pearson correlation coefﬁcient
(r)
Cord TSH (μIU/mL) 31 ↓: -0.069 ↑: 0.089 ↓: -0.088 -
Cord TT4 (μg/dL) 35 ↓: -0.111 ↓: -0.157 ↓: -0.048 -
Cord TT3 (ng/dL) 34 ↓: -0.178 ↓: -0.240 ↓: -0.157 -
↑ Positive association; ↓ negative association; * pb0.05; - not studied; b: boys; CI: conﬁdence interval; FT4: free thyroxin; g: girls; IQR: interquartile range; ln: natural log transformed; n: sample size; NS: non-signiﬁcant; PFAS: perﬂuoroalkyl sub-
stances; PFHxS: perﬂuorohexane sulfonate; PFNA: perﬂuorononanoic acid; PFOA: perﬂuorooctanoic acid; PFOS: perﬂuorooctane sulfonate; Q: quartile; TH: thyroid hormone; TSH: thyroid-stimulating hormone; TT4: total thyroxin; TT3: total triio-
dothyronine; yrs: years.
Some data not included in the articles were provided by authors (sample size of each model: Lopez-Espinosa et al.)
a Results for TSH but not for T3 or T4 are presented in Berg et al. p b0.05 for Q3 and Q4. Q1 is the reference group.
b IQRs (in ng/mL): 1.0(PFHxS), 0.4(PFNA), 1.4(PFOA) and 3.3(PFOS) in Webster et al.; 47.1, 38.5, 23.1, and 31.8 for 1-5, 6-10, 11-17, and 1-17 yrs groups (modeled in utero PFOA) in Lopez-Espinosa et al.
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Table 4
Summary of associations between child PFAS exposure (ng/mL) and THs.
Study Expression of results TH (units) n Associations between PFAS and THs
PFHxS PFOA PFOS PFNA
Lewis et al. (2015) % change (95% CI) in TH per
doubling in PFAS concentration
TSH (μIU/mL) 158 boys (12-19 yrs) ↑: 6.2 (-1.5, 14.5) ↑: 9.6 (-7.1, 29.4) ↑*: 12.3 (0.7, 25.2) ↑*: 16.3 (4.0, 30.2)
TT4 (μg/dL)a ↓: -2.1 (-4.4, 0.2) ↓: -1.6 (-6.6, 3.6) ↓: -1.1 (-4.4, 2.3) ↑: 0.6 (-2.9, 4.3)
FT4 (ng/dL) ↓: -1.5 (-3.5, 0.5) ↓: -0.6 (-4.9, 4.0) ↑: 0.6 (-2.4, 3.6) ↑: 2.6 (-0.5, 5.8)
TT3 (ng/dL) ↑: 0.2 (-1.9, 2.4) ↓: -1.9 (-6.4, 2.9) ↓: -1.6 (-4.7, 1.5) ↓: -1.1 (-4.2, 2.2)
FT3 (pg/mL) ↑: 0.0 (-1.4, 1.4) ↑: 0.8 (-2.2, 3.9) ↓: -0.3 (-2.3, 1.7) ↑: 0.3 (-1.8, 2.4)
TSH (μIU/mL) 145 girls (12-19 yrs) ↓: -4.1 (-11.8, 4.3) ↓*: -16.6 (-28.6, -2.6) ↓: -6.6 (-16.0, 3.8) ↑: 4.2 (-8.4, 18.5)
TT4 (μg/mL) ↓: -0.3 (-2.8, 2.1) ↑: 4.1 (-0.6, 8.9) ↓: -0.3 (-3.4, 2.8) ↓: -3.2 (-6.7, 0.5)
FT4 (ng/dL) ↑: 0.2 (-2.1, 2.6) ↑: 2.1 (-2.2, 6.7) ↑: 0.1 (-2.8, 3.1) ↓: -2.6 (-6.0, 8.9)
TT3 (ng/dL) ↓: -1.3 (-3.7, 1.1) ↑: 0.3 (-4.2, 5.1) ↓: -2.3 (-5.2, 0.8) ↓: -1.6 (-5.3, 2.2)
FT3 (pg/mL) ↓: -0.8 (-2.6, 1.1) ↑: 1.1 (-2.4, 4.7) ↓: -1.1 (-3.3, 1.3) ↓: -1.9 (-4.7, 0.9)
Lin et al. (2013) p for trendb lnTSH (μIU/L) 65 boys (12-19 yrs) - pN0.05 pN0.05 pN0.05
FT4 (ng/dL) - pN0.05 pN0.05 pN0.05
lnTSH (μIU/L) 144 girls (12-19 yrs) - pN0.05 pN0.05 pN0.05
FT4 (ng/dL) - pN0.05 pN0.05 pN0.05
Lopez-Espinosa et al., 2012b % change (95% CI) in TH per IQRc
ng/mL increase in PFAS
TSH (μIU/mL) 3,328 boys (11-17 yrs) - ↑: 1.6 (-1.1, 4.3) ↑: 1.1 (-1.0, 3.2) ↑*: 2.0 (0.0, 4.0)
TT4 (μg/dL) 3,334 boys (11-17 yrs) - ↑ : 0.5 (-0.5, 1.4) ↑* : 1.2 (0.5, 2.0) ↑* : 1.9 (1.2, 2.6)
TSH (μIU/mL) 3,062 girls (11-17 yrs) - ↑: 2.4 (-0.7, 5.7) ↑: 0.8 (-1.9, 3.5) ↑: 0.2 (-2.0, 2.4)
TT4 (μg/dL) 3,064 girls (11-17 yrs) - ↓ : -0.9 (-2.0, 0.2) ↑* : 1.1 (0.1, 2.0) ↑: 0.5 (-0.3, 1.3)
TSH (μIU/mL) 6,390 children (11-17 yrs) - ↑: 2.0 (-0.1, 4.1) ↑: 0.9 (-0.8, 2.7) ↑: 1.1 (-0.5, 2.8)
TT4 (μg/dL) 6,398 children (11-17 yrs) - ↓ : -0.3 (-1.1, 0.4) ↑* : 1.2 (0.6, 1.9) ↑* : 1.3 (0.7, 1.9)
TSH (μIU/mL) 1,586 boys (6-10 yrs) - ↓: -1.1 (-4.4, 2.3) ↓: -1.7 (-4.5, 1.2) ↓: -0.9 (-3.3, 1.6)
TT4 (μg/dL) 1,597 boys (6-10 yrs) - ↑: 0.1 (-1.1, 1.3) ↑: 0.4 (-0.7, 1.4) ↑: 0.5 (-0.4, 1.4)
TSH (μIU/mL) 1,475 girls (6-10 yrs) - ↑: 2.2 (-1.7, 6.3) ↑: 2.1 (-1.7, 5.7) ↑: 1.0 (-2.4, 4.4)
TT4 (μg/dL) 1,480 girls (6-10 yrs) - ↑: 1.9 (0.6, 3.2) ↑*: 1.5 (0.4, 2.7) ↑*: 1.4 (0.3, 2.5)
TSH (μIU/mL) 3,061 children (6-10 yrs) - ↑: 0.5 (-2.0, 3.1) ↑: 0.0 (-2.2, 2.3) ↑: 0.0 (-2.1, 2.1)
TT4 (μg/dL) 3,077 children (6-10 yrs) - ↑: 0.9 (0.0, 1.8) ↑*: 0.9 (0.2, 1.7) ↑*: 1.0 (0.3, 1.7)
TSH (μIU/mL) 471 boys (1-5 yrs) - ↓: -1.1 (-6.6, 4.7) ↑: 1.4 (-4.3, 7.5) ↓: -0.7 (-6.0, 4.8)
TT4 (μg/dL) 487 boys (1-5 yrs) - ↑: 1.3 (-0.7, 3.3) ↑: 0.4 (-1.7, 2.5) ↑: 1.1 (-0.8, 3.0)
TSH (μIU/mL) 500 girls (1-5 yrs) - ↓*: -7.7 (-13.2, -1.7) ↑: 4.7 (-0.9, 10.5) ↑: 1.5 (-3.8, 7.1)
TT4 (μg/dL) 510 girls (1-5 yrs) - ↓: -0.1 (-2.2, 2.0) ↑: 1.2 (-0.6, 3.0) ↑: 1.1 (-0.7, 2.9)
TSH (μIU/mL) 971 children (1-5 yrs) - ↓*: -4.3 (-8.2, -0.3) ↑: 3.1 (-0.9, 7.3) ↑: 0.2 (-3.5, 4.1)
TT4 (μg/dL) 997 children (1-5 yrs) - ↑: 0.7 (-0.7, 2.1) ↑: 0.8 (-0.6, 2.2) ↑: 1.1 (-0.2, 2.4)
TSH (μIU/mL) 5,385 boys (1-17 yrs) - ↑: 0.7 (-1.3, 2.7) ↑: 0.4 (-1.2, 2.1) ↑: 1.0 (-0.7, 2.6)
TT4 (μg/dL) 5,418 boys (1-17 yrs) - ↑: 0.4 (-0.3, 1.1) ↑*: 0.9 (0.3, 1.5) ↑*: 1.4 (0.9, 2.0)
TSH (μIU/mL) 5,037 girls (1-17 yrs) - ↑: 1.3 (-1.0, 3.8) ↑: 1.6 (-0.5, 3.6) ↑: 0.5 (-1.4, 2.5)
TT4 (μg/dL) 5,054 girls (1-17 yrs) - ↑: 0.0 (-0.8, 0.7) ↑*: 1.2 (0.5, 1.9) ↑*: 0.9 (0.2, 1.5)
TSH (μIU/mL) 10,422 children (1-17 yrs) - ↑: 1.0 (-0.5, 2.7) ↑: 1.0 (-0.3, 2.3) ↑: 0.8 (-0.4, 2.0)
TT4 (μg/dL) 10,472 children (1-17 yrs) - ↑: 0.1 (-0.5, 0.6) ↑*: 1.1 (0.6, 1.5) ↑*: 1.1 (0.7, 1.5)
↑ Positive association; ↓ negative association; * pb0.05; - not studied; CI: conﬁdence interval; FT3: free triiodothyronine; FT4: free thyroxin; IQR: interquartile range; ln: natural log transformed; n: sample size; PFAS: perﬂuoroalkyl substances; PFHxS:
perﬂuorohexane sulfonate; PFNA: perﬂuorononanoic acid; PFOA: perﬂuorooctanoic acid; PFOS: perﬂuorooctane sulfonate; TH: thyroid hormone; TSH: thyroid-stimulating hormone; TT4: total thyroxin; TT3: total triiodothyronine; yrs: years.
Some data not included in the articles were provided by authors (sample size of each model: Lopez-Espinosa et al.)
a Units for TT4 in Lewis et al. taken from: http://wwwn.cdc.gov/Nchs/Nhanes/2011-2012/THYROD_G.htm#LBXTT4.
b Authors reported mean and standard error of natural log transformed TSH and FT4 across categories of PFAS concentrations in linear regression models. Although associations were not signiﬁcant, mean levels of TSH increased across tertiles of
PFNA in boys.
c For the 1-5, 6-10, 11-17, and 1-17 years groups: 67.2, 63.4, 50.5, and 54.6 ng/mL (for PFOA), 12.9, 14.9, 12.6, and 13.3 ng/mL (for PFOS); and 0.8, 1.0, 0.8, and 0.8 ng/mL (for PFNA) in all children; 69.9, 63.1, 58.5, and 60.6 ng/mL (for PFOA), 13.0,
15.3, 12.9, and 13.7 ng/mL (for PFOS); and 0.8, 0.9, 0.7, and 0.8 ng/mL (for PFNA) in boys; and 64.6, 59.7, 41.2, and 48.4 ng/mL (for PFOA), 12.7, 14.1, 11.9, and 12.6 ng/mL (for PFOS); and 0.8, 1.1, 0.6, and 0.8 ng/mL (for PFNA) in girls.
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3.4.1. PFHxS and THs
Six papers analyzed the association between levels of PFHxS and
THs, ﬁve focusing on the prenatal (Table 3) and one on the postnatal
(Table 4) windows of exposure to this contaminant, respectively. Dur-
ing pregnancy, Wang et al. (2014) found statistically signiﬁcant associ-
ations between maternal PFHxS and TSH andWebster et al. (2014) and
Wang et al. (2013) found non-signiﬁcant increases in maternal TSH as-
sociated to maternal PFHxS. No signiﬁcant associations with T3 or T4
were reported in any study.
3.4.2. PFOA and THs
Nine papers analyzed the association with this contaminant. Three
out of the seven studies focusing on prenatal PFOA exposure found sta-
tistically signiﬁcant associationswith eithermaternal or child hormones
measured at different lifestages (Table 3). Speciﬁcally, signiﬁcant posi-
tive associations between maternal PFOA and cord TSH (Kim et al.,
2011), PFOA modeled in utero and TT4 in children b6 years (Lopez-
Espinosa et al., 2012b), and cord PFOA and female newborn TT4 (de
Cock et al., 2014) were reported. Lopez-Espinosa et al. (2012b) also
stratiﬁed results by sex, ﬁnding similar but not signiﬁcant results for
the association between PFOA and TT4 (% change [95% CI]: 1.7%
[−1.2, 4.6%] and 2.1% [−0.5, 4.8%] in TT4 associated with a sex-
speciﬁc IQR increment in modeled in utero PFOA [18 to 88 ng/mL for
boys and 14 to 78 for girls]) in boys and girls aged b6 years (data not
shown). During childhood (Table 4), two out of three studies reported
statistically signiﬁcant associations between child PFOA and TSH
but at different ages during infancy. Only in the group of children aged
1–5 years, Lopez-Espinosa et al. (2012b) reported child serum PFOA
to be inversely associated with child TSH, this being signiﬁcant in
girls but not in boys and Lewis et al. (2015) reported a signiﬁcant in-
verse association between PFOA and TSH in girls aged 12–19 years.
The association in the group of girls aged 11–17 years, although not sig-
niﬁcant, was positive in the much larger study of Lopez-Espinosa et al.
(2012b).
3.4.3. PFOS and THs
Nine papers analyzed the association with this contaminant. During
gestation (Table 3), Berg et al. (2015) andWang et al. (2013) found a pos-
itive signiﬁcant association between maternal PFOS and TSH, Webster
et al. (2014) a non-signiﬁcant positive association and Wang et al.
(2014) a negative but close to null association. In addition, Kim et al.
(2011) found a signiﬁcant negative correlation between maternal PFOS
and cord TT3. Regarding child PFOS exposure (Table 4), Lopez-Espinosa
et al. (2012b) reported a positive association between PFOS and TT4 in
children aged 1–17 years. In this paper, this association remained signiﬁ-
cant in boys aged 11–17 years and 6–17 year-old girls when analyses
were stratiﬁed by age groups and sex. Lewis et al. (2015) reported a sig-
niﬁcant positive association between PFOS and TSH in boys aged 12–
19 years.
3.4.4. PFNA and THs
Seven papers analyzed the association between PFNA and THs,
four of them focused on the prenatal and three on the postnatal pe-
riods of exposure to this contaminant. During pregnancy (Table 3),
maternal PFNA concentrations were positively associated with ma-
ternal TSH in three out of four studies (Wang et al., 2013, 2014;
Webster et al., 2014), but statistical signiﬁcance was only reached
in one of them (Webster et al., 2014). PFNA was also inversely
Table 5
Summary of associations between PFAS (ng/mL) and thyroid dysfunctions.
Study Expression of results Thyroid outcome n Associations between PFAS and thyroid dysfunction
PFHxS PFOA PFOS PFNA
Maternal PFAS
Berg et al., 2015 Number of women with
subclinical hypothyroidisma in
each PFAS quartile
Subclinical hypothyroidisma - - Q1: n=12 -
Q2: n=16
Q3: n=24
Q4: n=30
Webster et al. (2014) % change (95% CI) in THs per
IQRb ng/mL increase in PFAS
compared to the medianc THs, in
women with high TPOAbd
Maternal TSH (μIU/L) 14 2 (-45, 48) 54 (8, 100)* 69 (15, 123)* 46 (8, 85)*
Maternal TT4 (nmol/L) 14 -6 (-17, 5) -6 (-17, 5) -7 (-21, 6) -2 (-11, 6)
Maternal FT4 (pmol/L) 14 -5 (-15, 4) -4 (-14, 5) -7 (-18, 3) -3 (-11, 4)
Wang et al. (2013) OR (95% CI) TSH dichotomizede 5%c NS NS NS NS
Lopez-Espinosa et al., 2012b OR (95% CI) of thyroid disease in
children per IQRb increase in
modeled in utero PFOA
Reported thyroid disease 27 - 1.47 (0.95, 2.27) - -
Reported hypothyroidism 20 - 1.61 (0.96, 2.63) - -
Subclinical hypothyroidismf 155 - 0.94 (0.76, 1.16) - -
Subclinical hyperthyroidismf 31 - 1.10 (0.69, 1.74) - -
Chan et al. (2011) OR (95% CI) Hypothyroxinemiag 271 1.12 (0.89, 1.41) 0.94 (0.74, 1.18) 0.88 (0.63, 1.24) -
Child PFAS
Lopez-Espinosa et al., 2012b OR (95% CI) of thyroid disease in
children per IQRb increase in
PFAS
Reported thyroid disease 61 - 1.44 (1.02, 2.03)* 0.80 (0.62, 1.08) 1.05 (0.78, 1.41)
Reported hypothyroidism 39 - 1.54 (1.00, 2.37)* 0.91 (0.63, 1.31) 1.11 (0.77, 1.60)
Subclinical hypothyroidismf 365 - 0.98 (0.86, 1.15) 0.99 (0.86, 1.13) 0.99 (0.88, 1.12)
Subclinical hyperthyroidismf 78 - 0.81 (0.58, 1.15) 0.80 (0.62, 1.02) 0.78 (0.61,1.01)
* pb0.05; - not studied; CI: Conﬁdence interval; FT4: free thyroxin; IQR: interquartile range; n: sample size of participants with thyroid dysfunction; NS: non-signiﬁcant; OR: odds ratio;
PFAS: perﬂuoroalkyl substances; PFHxS: perﬂuorohexane sulfonate; PFNA: perﬂuorononanoic acid; PFOA: perﬂuorooctanoic acid; PFOS: perﬂuorooctane sulfonate; TH: thyroid hormone;
TPOAb: thyroid peroxidase antibody (dichotomized according to clinical guidelines, high: ≥9 IU/mL versus normal: b9 IU/mL); TSH: thyroid stimulating-hormone; TT4: total thyroxin.
a Subclinical hypothyroidism: depleted supply of T4/FT4 and T3/FT3.
b IQRs (in ng/mL): 1.0(PFHxS), 0.4(PFNA), 1.4(PFOA) and 3.3(PFOS) in Webster et al.; 31.8 (modeled in utero PFOA), 54.6 (child PFOA), 13.3 (child PFOS), and 0.8 (child PFNA) for
children aged 1-17 years in Lopez-Espinosa et al.
c Medians in the whole study: 1.3 mIU/L at 15 weeks (TSH), 9.5 pmol/L at 15 weeks (FT4), and 126.4 nmol/L at 15 weeks (TT4).
d Webster et al. assessed the effect of PFAS in womenwith TPOAb levels including the interaction between TPOAb status and PFAS in the models. For PFHxS, PFOA, PFOS, and PFNA: p
interaction = 0.97, 0.05, 0.03, 0.05 (for TSH); 0.30, 0.37, 0.40, 0.82 (for TT4); and 0.23, 0.40, 0.15, 0.37 (for FT4).
e TSH N95th percentile (7.5 μIU/mL) or below.
f TT4 within the normal reference range (4.5–12 μg/dL) and TSH N5.97, N4.84, N4.5 μIU/mL in children b6, 6–10, 11-17 years of age for subclinical hypothyroidism and TSH b0.7, b0.6,
b0.45 μIU/mL in children b6, 6–10, 11-17 years of age for subclinical hyperthyroidism. Children who self-reported thyroid disease and/or thyroid medication were excluded.
g Hypothyroxinemia: deﬁned by authors as normalmaternal TSH levelswith no evidence of hyperthyroidism (0.15-≤4mU/L) andmaternal FT4 levels in the lowest 10th percentile (≤8.8
pmol/L) of the sample.
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associated with TT4, FT4, or TT3 in one study (Wang et al., 2014). Re-
garding child exposure (Table 4), Lopez-Espinosa et al. (2012b) re-
ported an increase in TT4 concentrations associated to serum PFNA
exposure in children aged 1–17 years. Sex-subgroup analyses re-
vealed that the association reached statistical signiﬁcance in 11–
17 year-old boys and girls aged 6–10 years. TSH levels also signiﬁcantly
increasedwith PFNA concentrations (Lewis et al., 2015; Lopez-Espinosa
et al., 2012b) and mean levels of TSH increased non-signiﬁcantly
across PFNA tertiles (Lin et al., 2013) in three studies of boys aged
11–19 years.
3.4.5. Direction of the associations
Tables 3 and 4 also show an arrow indicating the direction of the as-
sociation to allow evaluation of whether there is a tendency for effect
estimates to run in one direction, even if the effect is not statistically sig-
niﬁcant or close to null. For the studies usingmaternal levels of contam-
inants and hormones (n = 4), a clearer consistent direction in the
association was found between maternal PFHxS, PFOS, or PFNA and
TSH (positive) or T4 (negative). During childhood, a consistent direction
of the association (positive) was found for PFNA and TSH in boys aged
11–19 years (n= 3 studies). T3 was not studied sufﬁciently to draw a
conclusion.
3.5. Analysis of the relation between PFAS and thyroid dysfunctions
The number of studies on thyroid dysfunction is low (n= 5) and
few studies found statistically signiﬁcant associations (Table 5). Dur-
ing pregnancy, an increased proportion of women with subclinical
hypothyroidism for each PFOS quartile was reported (Berg et al.,
2015), and PFOA, PFOS, and PFNA were positively and statistically
signiﬁcantly associated with TSH levels in pregnant women with
high TPOAb (n = 14) (Webster et al., 2014). During infancy, a posi-
tive signiﬁcant association was found between reporting thyroid dis-
ease, mostly hypothyroidism, and serum PFOA concentrations in one
study. However, PFOA concentrations were not associated with sub-
clinical hypo/hyperthyroidism based on individual TH levels (Lopez-
Espinosa et al., 2012b).
Fig. 1. Box-plot of PFAS concentrations (ng/mL) in the different studies. PFAS: perﬂuoroalkyl substances; PFHxS: perﬂuorohexane sulfonate; PFNA: perﬂuorononanoic acid; PFOA:
perﬂuorooctanoic acid; PFOS: perﬂuorooctane sulfonate; T: trimester; y: years. Some data not included in the articles were provided by authors (percentiles: Berg et al. and de Cock
et al.; minimums and/or maximums: Lopez-Espinosa et al., Kim et al., and Wang et al. [2013 and 2014]; and descriptive data for children aged 12–19 years: Lin et al.). For Lewis et al.,
data for all children (n = 303) have been calculated using the publicly-available data from NHANES, 2011–2012 (NHANES, 2015), since Lewis et al. reported sex-stratiﬁed PFAS
concentrations. Descriptive data for controls but not cases were represented for Chan et al.
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3.6. Dose-response relationship
To investigate the relation between PFAS and THs, different ap-
proaches have been used: log transforming, or not, of the exposure and
outcome variables and categorizing exposure into percentiles. Only two
studies ﬁtted a linear relationship between PFAS and THs (Wang et al.,
2014; Webster et al., 2014). Wang et al. (2014) evaluated the possibility
of a non-monotonic relationship between each PFAS and each outcome
bymeans of generalized additivemodels and concluded therewas no ev-
idence of a departure from linearity. Finally, a linear relationship was
compared to ln-transformation of the THs with similar results (Wang
et al., 2014). Categorization of PFAS was conducted in six articles (Berg
et al., 2015; de Cock et al., 2014; Lewis et al., 2015; Lin et al., 2013;
Lopez-Espinosa et al., 2012b; Wang et al., 2013), but only one (Lin et al.,
2013) carried out a test for trend (p N 0.05 in all cases). The relationship
was apparently monotonic for maternal PFOS and TSH in Berg et al.
(2015) (Table 3) and for child PFOS (% change [95% CI]: Q2: 0.8% [−0.3,
1.8%], Q3: 0.9% [−0.2, 1.9%], Q4: 2.3% [1.2, 3.3%]) and PFNA (Q2: 0.8%
[−0.3, 1.8%], Q3: 1.7% [0.7, 2.8%], Q4: 2.7% [1.7, 3.8%]) in relation to
child TT4 (Lopez-Espinosa et al., 2012b). Finally, some studies reported
signiﬁcant positive associations between PFOS and lnTSH (Berg et al.,
2015; Lopez-Espinosa et al., 2012b; Wang et al., 2013), PFOA and TT4
(de Cock et al., 2014), and PFOS or PFNA and TT4 (Lopez-Espinosa et al.,
2012b) when comparing the third and/or fourth quartiles with the ﬁrst
one.
Some of the six studies using PFAS categorization considered at least
one other approach to assess the dose-response relationship. Lewis et al.
(2015) considered a linear relationship between log2-PFAS and log2-
THs, but also carried out a sensitivity analysiswith PFAS in quartiles to ex-
plore potential non-linearity of the relationships, and resultswere similar.
In de Cock et al. (2014), none of the contaminants showed a linear rela-
tionship with T4, and a PFAS categorization in quartiles was used in the
ﬁnal statistical models. Lastly, Lopez-Espinosa et al. (2012b) conducted
regressionmodels between lnPFAS or quartiles of PFAS and lnTSH or TT4.
4. Discussion
The literature (n= 77 articles retrieved) showed growing interest in
the role played by exposure to PFAS in thyroid outcomes. However, we
found very few relevant papers (n= 10) on this speciﬁc subject when
it comes to pregnant women, newborns, and children up to 19 years
old. In sum, therewere insufﬁcient numbers of studies in each population
group to make comparisons except in two cases: mothers (n= 4) and
11–19-year-old children (n=3). In both cases, no consistent associations
between four PFAS andTHs or thyroiddysfunctionswere foundexcept for
TSH levels. There was some evidence of a positive association between
PFHxS and PFOS exposure and levels of TSH measured in the blood of
mothers, aswell as PFNA and TSH levelsmeasured in the blood of teenage
boys. Differences in the expression of the results and/or effect estimates,
as well as the treatment of the outcome and exposure variables (e.g., log
transforming or not of data, continuous or categorical PFAS, etc.), prevented
us fromcombining effect estimates in ameta-analysis. Therefore, due to the
small number of studieswith comparable data, further studies arewarrant-
ed to conﬁrm the possible relationships outlined above.
In order to draw our conclusion, we have assessed the evidence of a
possible association between PFAS and thyroid function impairment by
assessing the exposure and outcomes, and, by using the Bradford-Hill
Criteria of consistency and coherence, strength of the association, tem-
porality, biological gradient, and biological plausibility (Hill, 1965).
The speciﬁc elements of the analysis for drawing our conclusion are ex-
plained in the following subsections.
4.1. PFAS assessment
There are no differences in the method of chemical analysis
employed to determine PFAS (LC/MS in all studies) and studies did
not differ markedly in the LOD or LOQ in spite of beingmeasured in dif-
ferent laboratories worldwide. However, there are differences in how
concentrations below these limits were handled: replacement by LOD
or LOQ/√2, LOD/2, or imputation based on expected data. Nevertheless,
the percentages of samples bLODor LOQwere small inmost of the stud-
ies, except for PFNA in some cases.
The articles also differ in the blood compartments used to determine
PFAS concentrations. Across-compartment comparisons have previous-
ly been assessed in two studies, showing a 1:1 PFAS concentration ratio
between plasma and serum in pregnant women (Manzano-Salgado
et al., 2015) and workers occupationally exposed to PFAS (Ehresman
et al., 2007). Therefore, determination in either compartment seems to
be a good proxy with which to estimate PFAS body burden, and these
differences might not inﬂuence the comparability of the exposure
results.
4.2. Hormone assessment
The studies do differ in the THsmeasured to assess effects, since, ex-
cept for TSH, which was measured in all but one article, the rest of the
hormones were determined in a lower number of studies. Therefore,
not all studies had information available on free THs, which reﬂect the
levels of biologically active hormones that are available to the tissues
and might have yielded more comprehensive information concerning
the thyroid regulatory system.
Differences in themethods used to analyze THsmight also be impor-
tant. Studies used different types of immunoassay methods for hor-
mone determination. However, some animal studies have criticized
the use of these techniques for the assessment of FT4. These researchers
hypothesized that the reduction in FT4 in the presence of PFOS could
have been due to negative bias in analog techniques, resulting from
competitive displacement of FT4 and the labeled FT4 analog from
serum and assay binding proteins in the presence of this contaminant
(Chang et al., 2007; Luebker et al., 2005). This concern prompted a
study of potential bias from the presence of PFAS in a human population
with typical U.S. serum PFOS concentrations but higher PFOA concen-
trations due to their proximity to a Teﬂon factory (Lopez-Espinosa
et al., 2012a). Such bias from theuse of an analogwith respect to dialysis
methods in experimental studies (Chang et al., 2007; Luebker et al.,
2005) was not observed in this human population (Lopez-Espinosa
et al., 2012a). According to the authors, possible differences in the re-
sults between animal and human studies could be due to the differences
in levels of exposure to PFAS (higher in rats than in humans) and also
the inter-species differences in the principal proteins that bind T4 (in
rats: albumin and transthyretin [TTR], and in humans: thyroxine-
binding globulin [TBG], while albumin and TTR play comparatively
less important roles), and their interaction with PFAS (Lopez-Espinosa
et al., 2012a).
4.3. Consistency and coherence
Comparisons across studieswere hampered by the differences in the
lifestages considered: prenatal life, childhood, or both periods. Maternal
THs were measured during the second or third trimester of pregnancy
and after giving birth, and child THs were determined at birth, during
the ﬁrst days of life, and throughout childhood. Divergences also exist
in sampling time of PFAS (maternal, cord, or child samples).
Bearing in mind the sample size and the direction, magnitude, and
signiﬁcance of the associations, there is some consistency of a positive
association between maternal exposure to some PFAS and maternal
TSH levels. The evidence seems to be stronger for PFOS and PFHxS, the
direction of the association being positive in all studies except in one
case (but the association was close to null). In all cases, PFAS and THs
were measured in either the second or third trimester of pregnancy ex-
cept for Berg et al. (2015), which measured THs during the second tri-
mester and twice after birth. The same group has recently published a
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multipollutant approach on exposure to maternal PFAS and other per-
sistent organic pollutants and alterations in TH levels in the same pop-
ulation, but this time relating exposure to these contaminants with
hormones measured in samples collected in the second trimester of
pregnancy (Berg et al., 2016, not included in this review since the date
of publication is later than December 2015) and results are coherent
with those reported in the ﬁrst article (Berg et al., 2015).
All the cross-sectional studies on infancy examined children in sim-
ilar age ranges, between 11 and 19 years old, thus enabling us to com-
pare them. Consistency in direction (positive in the three studies) and
statistically signiﬁcant associations (in two cases) were found for
PFNA and TSH in boys aged ≥11 years. In girls, there was little evidence
of any association.
Concerning longitudinal studies on prenatal PFAS exposure and cord
or child THs levels, there were few articles with comparable data, and
their results showed little or no evidence of an effect.
Some studies also addressed the question of whether there was any
health effect associated with hormonal changes, which is essential for
understanding the clinical implication of the observed results. For that
reason, several thyroid diseases were investigated. The evidence of an
association is not clear, due to the few studies focused on thyroid dys-
functions, the small number of cases with these types of dysfunctions,
the discrepancy in the outcomes studied, differences in lifestages stud-
ied, and the few studies with statistically signiﬁcant associations. How-
ever, coherence was found in a study which reported an increased
proportion of mothers with subclinical hypothyroidism for each PFOS
quartile and an inverse relationship between PFOS and TSH (Berg
et al., 2015). In addition, higher PFAS concentrations were found in
pregnant women with additional thyroid stressors (high TPOAb)
(Webster et al., 2014). These ﬁndings are coherentwith results showing
an association with some PFAS found in U.S. adults with low iodine and
high TPOAb, both of which are stressors to the thyroid system (Webster
et al., 2015). During childhood, although higher odds of self-reported
thyroid disease, mostly hypothyroidism, associated to increased PFOA
concentrations were reported in one study, these results were not con-
sistent with an association between PFOA and TH levels for all children
combined or with the associations for the categories of sub-clinical
hypo/hyperthyroidism which were created using hormonal levels at
the time of the survey (Lopez-Espinosa et al., 2012b).
4.4. Strength of the association
Several aspects make it difﬁcult to assess the strength of the associ-
ation across studies. There is a substantial variation among the studies
in the estimates of the association (regression coefﬁcients, % change, es-
timated mean differences, Pearson correlation coefﬁcient, and p for
trend). Although PFAS concentrations were measured in the same
units (ng/mL), contaminantswere not treated in the sameway (contin-
uous or categorical) in the statistical analyses, which also hampers com-
parison among studies.
Another important issuewhen discussing the strength of association
is the control for confounding variables, and there was heterogeneity
across studies in this respect. Several variables known to inﬂuence thy-
roid status and PFAS, such as BMI, are not addressed in all the studies.
Some studies adjusted models for this variable (Berg et al., 2015; de
Cock et al., 2014; Kim et al., 2011; Lewis et al., 2015), others checked
whether it was a possible confounder but ﬁnally it was not included
(Lopez-Espinosa et al., 2012b; Wang et al., 2013, 2014) and the rest
did not include it in the statistical analysis. The adjustment of models
for BMI is under debate, since BMI might be causally “downstream” of
both exposure (PFAS) and outcome (THs) variables (Webster et al.,
2014). Most studies did not measure other important biomarkers
whichmight affect TH levels, such as iodine status or thyroid antibodies.
Some studies (Lopez-Espinosa et al., 2012b; Wang et al., 2013, 2014;
Webster et al., 2014) excluded people with thyroid diseases or thyroid
treatments, as they receive medication prescribed to adjust hormones
to normal levels. However, some studies did not make such exclusions
and the medications could thus obscure the association, if present, for
those individuals.
Study populations are likely to be exposed tomultiple chemical con-
taminants at the same time and, therefore, multipollutant analyses in-
cluding other PFAS were conducted in some of the studies reviewed
(Berg et al., 2015; Chan et al., 2011; Lin et al., 2013; Lopez-Espinosa
et al., 2012b). The magnitude of the associations was similar across
studies except for Berg et al. (2015), where the associations between
PFHxS or PFOA and TSH were no longer signiﬁcant after including
PFOS, but results were not reported in the article and have not been
discussed in this review.While the combined thyroid effects of chemical
mixtures are certainly possible, since other chemical substances with
endocrine-disrupting properties and with similar sources of exposure
such as diet have been associated with alterations of TH levels in some
previous studies (Boas et al., 2012), it is important to mention the low
correlation between human serum levels of PFAS and other chemicals
measured in blood or urine, such as polybrominated diphenyl ethers,
organochlorine compounds, polychlorinated biphenyls, bisphenols,
and phtalates (Fisher et al., 2016; Robinson et al., 2015). This low corre-
lation gives some reassurance that PFAS, and not other TH disruptors,
are likely to be driving the associations seen in these studies.
Regardless of all the above limitations, signiﬁcant changes in TH
levels due to PFAS exposure seem to be, in general, small (except a β
of 38.6 nmol/L in female newborn TT4 when comparing the highest
and the lowest cord PFOA quartiles in de Cock et al. (2014)). Neverthe-
less, it is important to take into account that associations of a smallmag-
nitude can also be important in critical windows of exposure, such as
gestation or childhood, when even small shifts in THs could have irre-
versible consequences in brain development (de Escobar et al., 2004).
4.5. Temporality
Studies varied in the epidemiological design: cross-sectional, case-
control, or cohort. Cross-sectional studies are unable to establish a tem-
poral sequence due to the simultaneous measurement of exposure and
outcome. For example, there is some literature showing that THs can af-
fect kidney function (Chonchol et al., 2008), and excretion rates and
serum PFAS levels can depend on kidney function (Watkins et al.,
2013). Therefore, this factor associated with THs could be affecting the
cross-sectional relationship. In addition, effects may occur some time
after exposure and thus they could not be observed at the time of the
cross-sectional study.
Most of the longitudinal studies reported a single exposure mea-
sure. When using biomarkers, reliance on an exposure measurement
at only one time-point is not ideal. However, PFAS have a long half-
life (Bartell et al., 2010; Olsen et al., 2007), and published intraclass
coefﬁcients between the ﬁrst and third trimester measurements
are quite high (0.64–0.83) (Fisher et al., 2016). Thus, these measure-
ments can be considered as being reasonably representative of
serum levels during pregnancy, even if they do not allow the charac-
terization of cumulative exposure, exposure trajectory over time, or
windows of susceptibility to the contaminants. When information
was provided, maternal serum concentrations were slightly higher
than cord serum (Kim et al., 2011).
Concerning THs, it is preferable to compare effects across studies at
the same lifestage, since TH levels change quickly during the different
trimesters of pregnancy (Kapelari et al., 2008) and infancy (Hume
et al., 2004), and, therefore, differences across lifestages are to be
expected.
4.6. Biological gradient (dose-response relationship)
The shape of a possible dose-response relationship is not yet known.
Some studies have ﬁtted untransformed and others log-transformed
data for both PFAS and THs. For PFHxS and PFNA, the range of exposures
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is quite narrow and pretty similar among all studies reporting serum
levels. Therefore, they are uninformative for exploring the shape of
any relationship over a wider range. For PFOA and PFOS, the range of
the median values is wider, although the data we have are too sparse
to reach conclusions about the overall shape of the relationship, since
the assessment of whether the relationship varied by exposure range
would require more studies within each study type (maternal, cord,
and child) and the results with stronger associations are not consistent-
ly in the high or low serum level studies.
4.7. Biological plausibility
Interactions between the hypothalamic–pituitary–thyroid axis
can be inhibited or stimulated by natural physiological responses
or by exposure to chemical pollutants with endocrine disrupting
properties, such as PFAS (Jensen and Leffers, 2008). Although further
investigation is warranted, it has been proposed that PFASmay inter-
fere with thyroid homeostasis through various mechanisms, includ-
ing regulation of hepatic glucuronidation enzymes and deiodinases
in the thyroid gland, as reported in studies of exposed rat tissues
(Yu et al., 2009), by competition with T4 for binding to protein TTR
as seen in studies of exposed rat tissues (Weiss et al., 2009), by alter-
ing the expression of genes involved in TH signaling, as reported in
salmon embryos and larvae (Spachmo and Arukwe, 2012), or by al-
tering the function of nuclear hormone receptors, as reported in
zebraﬁsh embryos (Du et al., 2013).
Leaving aside the inter-species diversity due to differences in
modes of action and the generally high exposure in the experimental
studies, some animal evidence on the interference of these sub-
stances with the thyroid system exists. For example, decreased T3
and T4 levels after short-term or long-term PFOS/PFOA exposure
were found in animal studies (Boas et al., 2012). Experimental stud-
ies on PFHxS and PFNA exposure are scarcer, although both altered
TH function in in vitro tests (Long et al., 2013), PFHxS reduced plasma
TH levels in a concentration-dependent manner in an in ovo study
(Cassone et al., 2012), and long-term PFNA exposure raised T3 levels
in zebraﬁsh (Liu et al., 2011).
According to the existing scientiﬁc understanding of the functioning
of the hypothalamic–pituitary–thyroid axis, TSH levels should be in-
versely proportional to T4 and T3 levels at the same lifestage. TSH regu-
lates the synthesis and secretion of THs by the thyroid gland. In turn,
THs negatively inﬂuence TSH secretion from the anterior pituitary
gland through a negative feedback loop (Dietrich et al., 2012). However,
this relationship between these hormone levels was not observed con-
sistently in the epidemiological studies reviewed, since an increase in
TSH was not always associated with a reduction in T4 and/or T3 levels
or vice versa, when data were available.
5. Conclusion
In conclusion, heterogeneity was found across studies in terms of
study design, study setting, timing of PFAS exposure assessment,
timing and type of thyroid-related outcome assessment, adjustment
for potential confounders, and statistical approach. As a conse-
quence, there were insufﬁcient numbers of comparable studies in
each population group except for two cases: mothers and 11–19-
year-old children. Based on the current literature, we found some
consistency of a positive association between PFHxS and PFOS in re-
lation to TSH levels measured in maternal blood and PFNA and TSH
levels measured in the blood of boys aged ≥11 years. However, fur-
ther studies are warranted to conﬁrm these possible relationships.
Future studies should measure FT4 as well as TSH in order to yield
more comprehensive information concerning any effects on the
functioning of the hypothalamic-pituitary-thyroid axis. They should
preferably be longitudinal, and should include, if possible, repeated
measures of PFAS and thyroid outcomes in order to identify any pe-
riods of extra vulnerability.
Declaration of interests
There is no conﬂict of interest in this review. The authors' afﬁliation
is as shown on the cover page. The authors have sole responsibility for
the writing and content of the paper.
Acknowledgments
The authors are grateful to some of the authors of the articles included
in the present review (Berg V, de Cock M, Lin CY, Kim S, Longnecker M,
and Wang SL) for extra descriptive data provided for Table 1 and Fig. 1.
This study was funded by grants from the EU (FP7-ENV-2011 cod
282957 and HEALTH.2010.2.4.5-1), and from Spain: Instituto de Salud
Carlos III (Red INMA G03/176, CB06/02/0041, and FIS-FEDER: PI03/
1615, PI04/1509, PI04/1112, PI04/1931, PI05/1079, PI05/1052, PI06/
1213, PI07/0314, PI09/02647, PI11/01007, PI11/02591, PI11/02038,
PI13/1944, PI13/2032, PI14/00891, PI14/01687, and Miguel Servet-
FEDER CP11/0178) and the Conselleria de Sanitat, Generalitat Valenciana.
The main author also wishes to thank the directors at OSMAN, Antonio
Daponte Codina and Pilar Rueda de la Puerta, for their support.
Appendix A. Supplementary data
Supplementary data to this article can be found online at doi:10.
1016/j.envint.2016.10.015.
References
Anderson, G.W., 2001. Thyroid hormones and the brain. Front. Neuroendocrinol. 22 (1):
1–17. http://dx.doi.org/10.1006/frne.2000.0208.
Asvold, B.O., Bjøro, T., Nilsen, T.I.L., Vatten, L.J., 2007. Association between blood pressure
and serum thyroid-stimulating hormone concentration within the reference range: a
population-based study. J. Clin. Endocrinol. Metab. 92 (3):841–845. http://dx.doi.org/
10.1210/jc.2006-2208.
Bartell, S.M., Calafat, A.M., Lyu, C., Kato, K., Ryan, P.B., Steenland, K., 2010. Rate of decline in
serum PFOA concentrations after granular activated carbon ﬁltration at two public
water systems in Ohio and West Virginia. Environ. Health Perspect. 118 (2):
222–228. http://dx.doi.org/10.1289/ehp.00108s3511 .
Berg, V., Nøst, T.H., Hansen, S., Elverland, A., Veyhe, A.S., Jorde, R., et al., 2015. Assessing
the relationship between perﬂuoroalkyl substances, thyroid hormones and binding
proteins in pregnant women; a longitudinal mixed effects approach. Environ. Int.
77:63–69. http://dx.doi.org/10.1016/j.envint.2015.01.007.
Berg, V., Nøst, T., Pettersen, R., Hansen, S., Veyhe, A., Jorde, R., et al., 2016. Persistent organ-
ic pollutants and the association with maternal and infant thyroid homeostasis: a
multipollutant assessment. Environ. Health Perspect. http://dx.doi.org/10.1289/
EHP152 (in press).
Bernal, J., 2007. Thyroid hormone receptors in brain development and function. Nat Clin
Pract Endocrinol Metab 3 (3):249–259. http://dx.doi.org/10.1038/ncpendmet0424
(Mar).
Biondi, B., Palmieri, E.A., Klain, M., Schlumberger, M., Filetti, S., Lombardi, G., 2005. Sub-
clinical hyperthyroidism: clinical features and treatment options. Eur. J. Endocrinol.
152 (1):1–9. http://dx.doi.org/10.1530/eje.1.01809.
Boas, M., Feldt-Rasmussen, U., Main, K.M., 2012 May 22. Thyroid effects of endocrine
disrupting chemicals. Mol. Cell. Endocrinol. 355 (2):240–248. http://dx.doi.org/10.
1016/j.mce.2011.09.005.
Cassone, C.G., Vongphachan, V., Chiu, S., Williams, K.L., Letcher, R.J., Pelletier, E., et al.,
2012. In ovo effects of perﬂuorohexane sulfonate and perﬂuorohexanoate on pipping
success, development, mRNA expression, and thyroid hormone levels in chicken em-
bryos. Toxicol. Sci. 127 (1):216–224. http://dx.doi.org/10.1093/toxsci/kfs072.
Chan, E., Burstyn, I., Cherry, N., Bamforth, F., Martin, J.W., 2011. Perﬂuorinated acids and
hypothyroxinemia in pregnant women. Environ. Res. 111 (4):559–564. http://dx.
doi.org/10.1016/j.envres.2011.01.011.
Chang, S.C., Thibodeaux, J.R., Eastvold, M.L., Ehresman, D.J., Bjork, J.A., Froehlich, J.W., et al.,
2007. Negative bias from analog methods used in the analysis of free thyroxine in rat
serum containing perﬂuorooctanesulfonate (PFOS). Toxicology 234 (1–2):21–33.
http://dx.doi.org/10.1016/j.tox.2007.01.020.
Chonchol, M., Lippi, G., Salvagno, G., Zoppini, G., Muggeo, M., Targher, G., 2008. Prevalence
of subclinical hypothyroidism in patients with chronic kidney disease. Clin. J. Am. Soc.
Nephrol. 3 (5):1296–1300. http://dx.doi.org/10.2215/CJN.00800208.
De Cock, M., de Boer, M.R., Lamoree, M., Legler, J., de Bor M., v., 2014. Prenatal exposure to
endocrine disrupting chemicals in relation to thyroid hormone levels in infants - a
Dutch prospective cohort study. Environ. Health 13:106. http://dx.doi.org/10.1186/
1476-069x-13-106.
Dietrich, J.W., Landgrafe, G., Fotiadou, E.H., 2012. TSH and thyrotropic agonists: key actors
in thyroid homeostasis. J. Thyroid. Res. 2012, 351864. http://dx.doi.org/10.1155/
2012/351864.
26 V. Ballesteros et al. / Environment International 99 (2017) 15–28
Domingo, J.L., Ericson-Jogsten, I., Perelló, G., Nadal, M., Van Bavel, B., Kärrman, A., 2012.
Human exposure to perﬂuorinated compounds in Catalonia, Spain: contribution of
drinking water and ﬁsh and shellﬁsh. J. Agric. Food Chem. 60:4408–4415. http://dx.
doi.org/10.1021/jf300355c.
Du, G., Hu, J., Huang, H., Qin, Y., Han, X., Wu, D., et al., 2013. Perﬂuorooctane sulfonate
(PFOS) affects hormone receptor activity, steroidogenesis, and expression of
endocrine-related genes in vitro and in vivo. Environ. Toxicol. Chem. 32 (2):
353–360. http://dx.doi.org/10.1002/etc.2034.
Dussault, J.H., Ruel, J., 1987. Thyroid hormones and brain development. Annu. Rev. Phys-
iol. 49:321–334. http://dx.doi.org/10.1146/annurev.ph.49.030187.001541.
Ehresman, D.J., Froehlich, J.W., Olsen, G.W., Chang, S.C., Butenhoff, J.L., 2007. Comparison of
human whole blood, plasma, and serum matrices for the determination of
perﬂuorooctanesulfonate (PFOS), perﬂuorooctanoate (PFOA), and other
ﬂuorochemicals. Environ. Res. 103 (2):176–184. http://dx.doi.org/10.1016/j.envres.
2006.06.008.
de Escobar, G.M., Obregón, M.J., del Rey, F.E., 2004. Maternal thyroid hormones early in
pregnancy and fetal brain development. Best Pract. Res. Clin. Endocrinol. Metab. 18
(2):225–248. http://dx.doi.org/10.1016/j.beem.2004.03.012.
Fisher, M., Arbuckle, T.E., Liang, C.L., LeBlanc, A., Gaudreau, E., Foster, W.G., et al., 2016.
Concentrations of persistent organic pollutants in maternal and cord blood from
the maternal-infant research on environmental chemicals (MIREC) cohort study. En-
viron. Health 15 (1):59. http://dx.doi.org/10.1186/s12940-016-0143-y.
Freire, C., Ramos, R., Amaya, E., Fernandez, M.F., Santiago-Fernandez, P., Lopez-Espinosa,
M.J., et al., 2010. Newborn TSH concentration and its associationwith cognitive devel-
opment in healthy boys. Eur. J. Endocrinol. 163 (6):901–909. http://dx.doi.org/10.
1530/eje-10-0495.
Fromme, H., Tittlemier, S.A., Völkel, W., Wilhelm, M., Twardella, D., 2009. Perﬂuorinated
compounds–exposure assessment for the general population in Western countries.
Int. J. Hyg. Environ. Health 212 (3):239–270. http://dx.doi.org/10.1016/j.ijheh.2008.04.
007.
González-Alzaga, B., Lacasaña, M., Aguilar-Garduño, C., Rodríguez-Barranco, M., Ballester,
F., Rebagliato, M., Hernández, A.F., 2014. A systematic review of neurodevelopmental
effects of prenatal and postnatal organophosphate pesticide exposure. Toxicol. Lett.
230 (2):104–121. http://dx.doi.org/10.1016/j.toxlet.2013.11.019.
Haddow, J.E., Palomaki, G.E., Allan, W.C., Williams, J.R., Knight, G.J., Gagnon, J., et al., 1999.
Maternal thyroid deﬁciency during pregnancy and subsequent neuropsychological
development of the child. N. Engl. J. Med. 341 (8):549–555. http://dx.doi.org/10.
1056/nejm199908193410801.
Hill, A.B., 1965. The environment and disease: association or causation? Proc. R. Soc. Med.
58:295–300. http://dx.doi.org/10.1177/0141076814562718.
Hume, R., Simpson, J., Delahunty, C., van Toor, H., Wu, S.Y., Williams, F.L.R., et al., 2004.
Human fetal and cord serum thyroid hormones: developmental trends and interrela-
tionships. J. Clin. Endocrinol. Metab. 89 (8):4097–4103. http://dx.doi.org/10.1210/jc.
2004-0573.
Inoue, K., Okada, F., Ito, R., Kato, S., Sasaki, S., Nakajima, S., et al., 2004. Perﬂuorooctane sul-
fonate (PFOS) and related perﬂuorinated compounds in human maternal and cord
blood samples: assessment of PFOS exposure in a susceptible population during preg-
nancy. Environ. Health Perspect. 112 (11):1204–1207. http://dx.doi.org/10.1289/ehp.
6864.
Jensen, A.A., Leffers, H., 2008. Emerging endocrine disrupters: perﬂuoroalkylated sub-
stances. Int. J. Androl. 31 (2):161–169. http://dx.doi.org/10.1111/j.1365-2605.2008.
00870.x.
Julvez, J., Alvarez-Pedrerol, M., Rebagliato, M., Murcia, M., Forns, J., Garcia-Esteban, R., et
al., 2013. Thyroxine levels during pregnancy in healthy women and early child
neurodevelopment. Epidemiology 24 (1):150–157. http://dx.doi.org/10.1097/ede.
0b013e318276ccd3.
Kapelari, K., Kirchlechner, C., Högler, W., Schweitzer, K., Virgolini, I., Moncayo, R., 2008.
Pediatric reference intervals for thyroid hormone levels from birth to adulthood: a
retrospective study. BMC Endocr. Disord. 8:15. http://dx.doi.org/10.1186/1472-
6823-8-15.
Kato, K., Wong, L.Y., Jia, L.T., Kuklenyik, Z., Calafat, A.M., 2011. Trends in exposure to
polyﬂuoroalkyl chemicals in the U.S. population: 1999–2008. Environ. Sci. Technol.
4519:8037–8045. http://dx.doi.org/10.1021/es1043613.
Kim, S., Choi, K., Ji, K., Seo, J., Kho, Y., Park, J., et al., 2011. Trans-placental transfer of thir-
teen perﬂuorinated compounds and relations with fetal thyroid hormones. Environ.
Sci. Technol. 45 (17):7465–7472. http://dx.doi.org/10.1021/es202408a.
Krude, H., Schütz, B., Biebermann, H., von Moers, A., Schnabel, D., Neitzel, H., et al., 2002.
Choreoathetosis, hypothyroidism, and pulmonary alterations due to human NKX2-1
haploinsufﬁciency. J. Clin. Invest. 109 (4):475–480. http://dx.doi.org/10.1172/
jci0214341.
Lewis, R.C., Johns, L.E., Meeker, J.D., 2015. Serum biomarkers of exposure to Perﬂuoroalkyl
substances in relation to serum testosterone andmeasures of thyroid function among
adults and adolescents from NHANES 2011-2012. Int. J. Environ. Res. Public Health 12
(6):6098–6114. http://dx.doi.org/10.3390/ijerph120606098.
Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., Gøtzsche, P.C., Ioannidis, J.P.A., et al.,
2009. The PRISMA statement for reporting systematic reviews and meta-
analyses of studies that evaluate health care interventions: explanation and
elaboration. J. Clin. Epidemiol. 62 (10):e1–34. http://dx.doi.org/10.1016/j.
jclinepi.2009.06.006.
Lin, C.Y., Wen, L.L., Lin, L.Y., Wen, T.W., Lien, G.W., Hsu, H J]–>S.H.J., et al., 2013. The asso-
ciations between serum perﬂuorinated chemicals and thyroid function in adolescents
and young adults. J. Hazard. Mater. 244–5:637–644. http://dx.doi.org/10.1016/j.
jclinepi.2009.06.006.
Liu, Y., Wang, J., Fang, X., Zhang, H., Dai, J., 2011. The thyroid-disrupting effects of long-
term perﬂuorononanoate exposure on zebraﬁsh (Danio rerio). Ecotoxicology 20
(1):47–55. http://dx.doi.org/10.1007/s10646-010-0555-3.
Long, M., Ghisari, M., Bonefeld-Jørgensen, E.C., 2013. Effects of perﬂuoroalkyl acids on the
function of the thyroid hormone and the aryl hydrocarbon receptor. Environ. Sci.
Pollut. Res. Int. 20 (11):8045–8056. http://dx.doi.org/10.1007/s11356-013-1628-7.
Lopez-Espinosa, M.J., Fitz-Simon, N., Bloom, M.S., Calafat, A.M., Fletcher, T., 2012a. Com-
parison between free serum thyroxine levels, measured by analog and dialysis
methods, in the presence of perﬂuorooctane sulfonate and perﬂuorooctanoate.
Reprod. Toxicol. 33 (4):552–555. http://dx.doi.org/10.1016/j.reprotox.2011.04.002.
Lopez-Espinosa, M.J., Mondal, D., Armstrong, B., Bloom, M.S., Fletcher, T., 2012b. Thyroid
function and perﬂuoroalkyl acids in children living near a chemical plant. Environ.
Health Perspect. 120 (7):1036–1041. http://dx.doi.org/10.1289/ehp.1104370.
Luebker, D.J., York, R.G., Hansen, K.J., Moore, J.A., Butenhoff, J.L., 2005. Neonatal mortality
from in utero exposure to perﬂuorooctanesulfonate (PFOS) in Sprague-Dawley rats:
dose-response, and biochemical and pharamacokinetic parameters. Toxicology 215:
149–169. http://dx.doi.org/10.1016/j.tox.2005.07.019.
Manzano-Salgado, C.B., Casas, M., Lopez-Espinosa, M.J., Ballester, F., Basterrechea, M.,
Grimalt, J.O., et al., 2015. Transfer of perﬂuoroalkyl substances from mother to fetus
in a Spanish birth cohort. Environ. Res. 142:471–478. http://dx.doi.org/10.1016/j.
envres.2015.07.020.
Manzano-Salgado, C.B., Casas, M., Lopez-Espinosa, M.J., Ballester, F., Martinez, D.,
Ibarluzea, J., et al., 2016. Variability of perﬂuoroalkyl substance concentrations in
pregnant women by socio-demographic and dietary factors in a Spanish birth cohort.
Environ. Int. 92-93:357–365. http://dx.doi.org/10.1016/j.envint.2016.04.004.
Mendelson, C.R., Boggaram, V., 1991. Hormonal control of the surfactant system in fetal
lung. Annu. Rev. Physiol. 53:415–440. http://dx.doi.org/10.1146/annurev.ph.53.
030191.002215.
Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., 2010. Preferred reporting items for system-
atic reviews and meta-analyses: the PRISMA statement. Int. J. Surg. 8 (5):336–341.
http://dx.doi.org/10.1016/j.ijsu.2010.02.007.
Mondal, D., Lopez-Espinosa, M.J., Armstrong, B., Stein, C.R., Fletcher, T., 2012. Relation-
ships of perﬂuorooctanoate and perﬂuorooctane sulfonate serum concentrations be-
tween mother–child pairs in a population with perﬂuorooctanoate exposure from
drinking water. Environ. Health Perspect. 120:752–757. http://dx.doi.org/10.1289/
ehp.1104538.
Mørck, T.A., Nielsen, F., Nielsen, J.K.S., Siersma, V.D., Grandjean, P., Knudsen, L.E., 2015.
PFAS concentrations in plasma samples from Danish school children and their
mothers. Chemosphere 129:203–209. http://dx.doi.org/10.1016/j.chemosphere.
2014.07.018.
NHANES, 2015. Available:. http://www.cdc.gov/nchs/nhanes/search/nhanes11_12.aspx
2011-2012, (Accessed on 15 February 2016).
OCDE, 2005. Results of survey on production and use of PFOS, PFAS and PFOA, related
substances and products/mixtures containing these substances.Available at:. http://
www.oecd.org/ofﬁcialdocuments/publicdisplaydocumentpdf/?cote=ENV/JM/
MONO%282005%291&docLanguage=En (Accessed on 1 September 2015).
Olmos, M., Antelo, M., Vazquez, H., Smecuol, E., Maurino, E., Bai, J.C., 2008. Systematic re-
view andmeta-analysis of observational studies on the prevalence of fractures in coe-
liac disease. Dig. Liver Dis. 40:46–53. http://dx.doi.org/10.1016/j.dld.2007.09.006.
Olsen, G.W., Burris, J.M., Ehresman, D.J., Froehlich, J.W., Seacat, A.M., Butenhoff,
J.L., et al., 2007. Half-life of serum elimination of perﬂuorooctanesulfonate,
perﬂuorohexanesulfonate, and perﬂuorooctanoate in retired ﬂuorochemical
production workers. Environ. Health Perspect. 115 (9):1298–1305. http://dx.
doi.org/10.1289/ehp.10009.
Osman, F., Gammage, M.D., Sheppard, M.C., Franklyn, J.A., 2002. Clinical review 142: car-
diac dysrhythmias and thyroid dysfunction: the hidden menace? J. Clin. Endocrinol.
Metab. 87 (3):963–967. http://dx.doi.org/10.1210/jcem.87.3.8217.
Papi, G., Uberti, E.D., Betterle, C., Carani, C., Pearce, E.N., Braverman, L.E., Roti, E., 2007. Sub-
clinical hypothyroidism. Curr. Opin. Endocrinol. Diabetes Obes. 14 (3):197–208.
http://dx.doi.org/10.1097/med.0b013e32803577e7.
Renner, R., 2001. Growing concern over perﬂuorinated chemicals. Environ. Sci. Technol.
35 (7):154A–160A. http://dx.doi.org/10.1021/es012317k.
Robinson, O., Basagaña, X., Agier, L., de Castro, M., Hernandez-Ferrer, C., Gonzalez, J.R., et
al., 2015. The pregnancy exposome: multiple environmental exposures in the INMA-
Sabadell Birth Cohort. Environ. Sci. Technol. 49 (17):10632–10641. http://dx.doi.org/
10.1021/acs.est.5b01782.
Rice, D., Barone, S., 2000. Critical periods of vulnerability for the developing nervous sys-
tem: evidence from humans and animal models. Environ. Health Perspect. 108
(Suppl. 3):511–533. http://dx.doi.org/10.1289/ehp.00108s3511.
Ricci-Cabello, I., Ruiz-Perez, I., Olry de Labry-Lima, A., Marquez-Calderon, S., 2010. Do so-
cial inequalities exist in terms of the prevention, diagnosis, treatment, control and
monitoring of diabetes? A systematic review. Health Soc. Care Commun. 18:
572–587. http://dx.doi.org/10.1111/j.1365-2524.2010.00960.x.
Rodríguez-Barranco, M., Lacasaña, M., Aguilar-Garduño, C., Alguacil, J., Gil, F., González-
Alzaga, B., Rojas-García, A., 2013. Association of arsenic, cadmium andmanganese ex-
posure with neurodevelopment and behavioural disorders in children: a systematic
review and meta-analysis. Sci. Total Environ. 454–455:562–577. http://dx.doi.org/
10.1016/j.scitotenv.2013.03.047.
Schug, T.T., Blawas, A.M., Gray, K., Heindel, J.J., Lawler, C.P., 2015. Elucidating the links be-
tween endocrine disruptors and neurodevelopment. Endocrinology 156 (6):
1941–1951. http://dx.doi.org/10.1210/en.2014-1734.
Spachmo, B., Arukwe, A., 2012. Endocrine and developmental effects in Atlantic salmon
(Salmo salar) exposed to perﬂuorooctane sulfonic or perﬂuorooctane carboxylic
acids. Aquat. Toxicol. 108:112–124. http://dx.doi.org/10.1016/j.aquatox.2011.07.018.
Vestergren, R., Cousins, I.T., Trudel, D., Wormuth, M., Scheringer, M., 2008. Estimating the
contribution of precursor compounds in consumer exposure to PFOS and PFOA.
Chemosphere 73 (10):1617–1624. http://dx.doi.org/10.1016/j.chemosphere.2008.
08.011.
Von Elm, E., Altman, D.G., Egger, M., Pocock, S.J., Gøtzsche, P.C., Vandenbroucke, J.P., 2014.
The strengthening the reporting of observational studies in epidemiology (STROBE)
statement: guidelines for reporting observational studies. Int. J. Surg. 12 (12):
1495–1499. http://dx.doi.org/10.1016/j.ijsu.2014.07.013.
Wang, Y., Rogan, W.J., Chen, P.-C., Lien, G.-W., Chen, H.-Y., Tseng, Y.-C., et al., 2014.
Association between maternal serum perﬂuoroalkyl substances during pregnan-
cy and maternal and cord thyroid hormones: Taiwan maternal and infant cohort
study. Environ. Health Perspect. 122 (5):529–534. http://dx.doi.org/10.1289/
ehp.1306925.
Wang, Y., Starling, A.P., Haug, L.S., Eggesbo, M., Becher, G., Thomsen, C., et al., 2013. Asso-
ciation between perﬂuoroalkyl substances and thyroid stimulating hormone among
27V. Ballesteros et al. / Environment International 99 (2017) 15–28
pregnant women: a cross-sectional study. Environ. Health 12 (1):76. http://dx.doi.
org/10.1186/1476-069x-12-76.
Watkins, D.J., Josson, J., Elston, B., Bartell, S.M., Shin, H.-M., Vieira, V.M., et al., 2013. Expo-
sure to perﬂuoroalkyl acids and markers of kidney function among children and ad-
olescents living near a chemical plant. Environ. Health Perspect. 121 (5):625–630.
http://dx.doi.org/10.1289/ehp.1205838.
Webster, G.M., Teschke, K., Janssen, P.A., 2011. Recruitment of healthy ﬁrst-trimester preg-
nant women: lessons from the Chemicals, Health & Pregnancy study (CHirP). Matern.
Child Health J. 16 (2):430–438. http://dx.doi.org/10.1007/s10995-010-0739-8.
Webster, G.M., Venners, S.A., Mattman, A., Martin, J.W., 2014. Associations between
perﬂuoroalkyl acids (PFASs) and maternal thyroid hormones in early pregnancy: a
population-based cohort study. Environ. Res. 133:338–347. http://dx.doi.org/10.
1016/j.envres.2014.06.012.
Webster, G.M., Rauch, S.A., Ste Marie, N., Mattman, A., Lanphear, B.P., SA., V., 2015.
Cross-sectional associations of serum perﬂuoroalkyl acids and thyroid hormones
in U.S. adults: variation according to TPOAb and iodine status (NHANES
2007–2008). Environ. Health Perspect. 124 (7):935–942. http://dx.doi.org/10.
1289/ehp.1409589.
Weiss, J.M., Andersson, P.L., Lamoree, M.H., Leonards, P.E.G., van Leeuwen, S.P.J., Hamers,
T., 2009. Competitive binding of poly- and perﬂuorinated compounds to the thyroid
hormone transport protein transthyretin. Toxicol. Sci. 109 (2):206–216. http://dx.doi.
org/10.1093/toxsci/kfp055.
WHO (World Health Organization), 2013. State of the science of endocrine
disrupting chemicals −2012. An assessment of the state of the science of endo-
crine disruptors prepared by a Group of Experts for the United Nations Environ-
ment Programme andWorld Health Organization (Bergman Å, Heindel JJ, Jobling
S, Kidd KA, Zoeller RT, eds).Available:. http://apps.who.int/iris/bitstream/10665/
78101/1/9789241505031_eng.pdf (Accessed on 15 February 2016).
Yu, W.G., Liu, W., Jin, Y.H., 2009. Effects of perﬂuorooctane sulfonate on rat thyroid hor-
mone biosynthesis and metabolism. Environ. Toxicol. Chem. 28:990–996. http://dx.
doi.org/10.1897/08-345.1.
Zhao, Y.G., Wong, C.K.C., Wong, M.H., 2012. Environmental contamination, human expo-
sure and body loadings of perﬂuorooctane sulfonate (PFOS), focusing on Asian coun-
tries. Chemosphere 89 (4):355–368. http://dx.doi.org/10.1016/j.chemosphere.2012.
05.043.
28 V. Ballesteros et al. / Environment International 99 (2017) 15–28
